Screening Potential Drugs for the Development of NAFLD Based on Drug Perturbation Gene Set.

Abstract

Nonalcoholic fatty liver disease (NAFLD) has become one of the problems affecting the health of the population worldwide. The progressive disease includes nonalcoholic steatohepatitis (NASH) and fibrosis, which with no approved therapy, system identification of effective drugs remains challenging. In this work, we applicated drug perturbation gene set enrichment analysis to screen drugs for the development of NAFLD. A total 15490 small-molecule compounds were analyzed in our study; based on the p value of enrichment score, 7 small-molecule compounds were found to have a potential role in NASH and fibrosis. After pathway analyses, we found indoximod had effects on nonalcoholic fatty liver disease through regulated TNFa, AP-1, AKT, PI3K, etc. Furthermore, we established the NAFLD cell model with LO2 cells induced using PA; ELISA showed that the levels of TG, ALT, and AST were significantly improved by indoximod. In summary, our study offers optimal therapeutic drugs, which may provide novel insight into the precise treatment of NAFLD and promote researches.

• Authors: Zhengzheng Gao, Lina Dai, Haifeng Zhang
• Journal: Computational and mathematical methods in medicine (Comput Math Methods Med) Vol. 2022 Pg. 7606716 ( 2022) ISSN: 1748-6718 [Electronic] United States
• PMID: 35469222 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Zhengzheng Gao et al.

Topics

• Fibrosis
• Humans
• Liver (pathology)
• Non-alcoholic Fatty Liver Disease (drug therapy, genetics)